Erdos
Drugcapsule, 300mg
NCT Number: NCT02332044
The purpose of this study is to evaluate the drug-drug interaction between Erdosteine and Bepotastine besilate in healthy adult volunteers.
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
capsule, 300mg
tablet, 10mg
capsule 300mg and tablet 10mg
Time frame: Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment
Time frame: Multiple blood sample will be collected for 24 hours after last dosing in each of the treatment
Daewoong Pharmaceutical Co. LTD.
Industry
A Randomized, Open-label, Single Dose, Three-treatment, Three-period, Six-sequence Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Erdosteine and Bepotastine Besilate After Oral Administration in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01866852
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT07515417
Dyssomnias, Health Adult Subjects
Mecca, Saudi Arabia
View Trial DetailsNCT07400679
Body Weight, Healthy
New Haven, Connecticut, United States
View Trial DetailsNCT06972862
Behavior, Exercise
Lawrence, Kansas, United States
View Trial Details